Efficacy and safety of abdakibart (ABD), a humanized high affinity and potency IgG4 anti-IL-1β agent for treatment of moderate to severe hidradenitis suppurativa at Week 16; IHS4 subgroup and lesion type ANdT results of the Phase 2 placebo-controlled LOTUS Trial